Literature DB >> 34263940

Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI).

Nichola Cooper1, Adam Cuker2, Nicola Bonner3, Waleed Ghanima4,5, Drew Provan6, Mervyn Morgan7, Barbara Taylor8, Denise D'Alessio9, Donald Arnold10, Ricardo Viana11.   

Abstract

Immune thrombocytopenia (ITP) is an acquired immune-mediated disorder. Bleeding is the primary symptom that presents in varying severities. ITP has a negative impact on health-related quality of life (HRQoL). The ITP Life Quality Index (ILQI) was developed as a 10-item patient-reported outcome measure to assess impact on HRQoL in ITP. The objective of the present study was to confirm the content validity of the ILQI with a qualitative interview study in the UK involving 15 adult participants with ITP. Combined concept elicitation (CE) and cognitive debriefing (CD) interviews were conducted to explore the symptoms and impacts associated with ITP and confirm content validity of the draft ILQI. The CE phase elicited 14 ITP symptom concepts, including: bruising (all 15 patients, 100%), fatigue (14, 93·3%) and bleeding gums/blood blisters (13, 86·7%). Impacts included decreased ability to participate in sport (all 15 patients, 100%) and anxiety (12, 80%). The CD phase resulted in an adjustment to the ILQI recall period from 1 week to 'the past month'. Updates were made to improve relevance and response options. The qualitative interviews support the content validity of the ILQI and confirm that the concepts assessed are relevant and consistently understood and interpreted by adult patients with ITP.
© 2021 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  HRQoL; ILQI; Immune thrombocytopenia; content validity; qualitative

Mesh:

Year:  2021        PMID: 34263940     DOI: 10.1111/bjh.17694

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia.

Authors:  Ricardo Viana; Denise D'Alessio; Laura Grant; Nichola Cooper; Donald Arnold; Mervyn Morgan; Drew Provan; Adam Cuker; Quentin A Hill; Yoshiaki Tomiyama; Waleed Ghanima
Journal:  Adv Ther       Date:  2021-10-27       Impact factor: 3.845

2.  Japanese and French translation and linguistic validation of a patient-reported outcome tool to assess quality of life in patients with Immune Thrombocytopenia (ITP): the ITP Life Quality Index (ILQI).

Authors:  Yoshiaki Tomiyama; Stèphane Cheze; Laura Grant; Nicola Bonner; Sylvain Affinito; Mitsuhiro Nagano; Tanvi Rajput; Ricardo Viana
Journal:  Int J Hematol       Date:  2022-06-08       Impact factor: 2.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.